New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
06:07 EDTBRK.A, EMC, MSFT, IBM, DELL, BAOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Boeing (BA) offered a strong defense of its grounded 787 Dreamliner, spelled out details of proposed battery fixes and predicted the jets could be back in commercial service in a matter of weeks, the Wall Street Journal reports...Dallas Fed President Richard Fisher will address this year's Conservative Political Action Conference, an unusually political venue for a U.S. central banker, pushing his proposal to break up the biggest U.S. banks as the best way to avoid government bailouts of such firms, the Wall Street Journal reports...REUTERS: IBM (IBM) and EMC Corp. (EMC) are among firms in talks to buy privately held database web hosting company SoftLayer Technologies Inc, in a deal that could be over $2B, sources say, reports Reuters...Silver Lake Partners, the technology-focused private equity firm backing a $24.4B bid to take Dell (DELL) private, is close to raising $10B for its latest fund, exceeding its initial fundraising target on strong investor demand and confidence in the firm, sources say, Reuters reports...BLOOMBERG: Microsoft (MSFT) has sold about 1.5M Surface devices, sources say, a slow beginning in its bid to crack the tablet market to make up for slumping PC demand, Bloomberg reports...Chinese carmaker BYD Co., partially owned by Berkshire Hathaway (BRK.A), plans to sell new shares equivalent to as much as 20% of its Hong Kong-traded stock, sources say, reports Bloomberg.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use